0 citations0 references

COVID‐19 in children. II: Pathogenesis, disease spectrum and management

Journal of Paediatrics and Child Health2021Vol. 58(1), pp. 46–53

Citations Over TimeTop 1% of 2021 papers

Annaleise R. Howard‐Jones, David Burgner, Nigel W. Crawford, Emma Goeman, Paul Gray, Peter Hsu, Stephanie Kuek, Brendan McMullan, Shidan Tosif, Danielle Wurzel, Asha C Bowen, Margie Danchin, Archana Koirala, Ketaki Sharma, Daniel K. Yeoh, Philip N Britton

Abstract

The global disruption of the COVID-19 pandemic has impacted the life of every child either directly or indirectly. This review explores the pathophysiology, immune response, clinical presentation and treatment of COVID-19 in children, summarising the most up-to-date data including recent developments regarding variants of concern. The acute infection with SARS-CoV-2 is generally mild in children, whilst the post-infectious manifestations, including paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) and 'long COVID' in children, are more complex. Given that most research on COVID-19 has focused on adult cohorts and that clinical manifestations, treatment availability and impacts differ markedly in children, research that specifically examines COVID-19 in children needs to be prioritised.

Related Papers

→ And now for something completely different: from 2019-nCoV and COVID-19 to 2020-nMan(2020)27 cited
→ Pathogenesis and Pathophysiology of Nasal Polyps(2010)7 cited
Research Progresses in Pathophysiological Roles of Urotensin II in Plasma of Bronchial Asthma Patients(2009)
→ Fachinformationen zu SARS-CoV-2/COVID-19(2020)